Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Lidocaine Dermal Products
NCT03145207Phase 1Completed
- Sponsor
- University of Maryland, Baltimore
- Start
- Dec 2016
- Primary completion
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of lidocaine 10% oropharyngeal spray in postherpetic neuralgia (PHN) (7 arms), sponsored by University of Maryland, Baltimore. Primary endpoint: Maximum Serum Concentration at 15 hours. Started Dec 2016; status: completed.
02
Drugs
lidocaine 10% oropharyngeal spray
03
Conditions
postherpetic neuralgia (PHN)
Beyond the preview
Go deeper on NCT03145207.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03145207.